Medicine and Dentistry
Esophageal Adenocarcinoma
100%
Patient
80%
Survival
50%
Biological Marker
29%
Neoadjuvant Chemotherapy
28%
Barrett Esophagus
26%
Pancreas Adenocarcinoma
26%
Malignant Neoplasm
26%
Surgery
26%
Overall Survival
25%
Adenocarcinoma
23%
Combination Therapy
23%
Neoplasm
23%
Neoadjuvant Therapy
22%
Therapeutic Procedure
21%
Systematic Review
21%
Esophageal Cancer
19%
Cohort Analysis
17%
Recurrent Disease
17%
Prognosis
17%
COVID-19
15%
Exercise
15%
Pancreas Cancer
14%
Association
13%
Inpatient
13%
Dysplasia
12%
Diagnosis
12%
Cancer Cell
12%
Chemotherapy
11%
Marker
11%
Colorectal Cancer
11%
Meta-Analysis
11%
Autophagy
10%
Programmed Cell Death
10%
Stomach Cancer
10%
Phenotype
10%
Microsatellite Instability
10%
Immune Checkpoint Inhibitor
10%
Cohort Effect
10%
Cancer Surgery
10%
Abdominal Cancer
10%
Analysis
10%
Quality of Life
9%
Lymph Node
9%
Immunocompetent Cell
9%
Hazard Ratio
8%
Diseases
8%
Immunohistochemistry
7%
Receptor Expression
7%
Adjuvant Chemotherapy
7%
Biochemistry, Genetics and Molecular Biology
Survival
25%
Mutation
21%
Nested Gene
20%
Phenotype
16%
Development
15%
Protein
14%
Overall Survival
13%
Esophagus
13%
Oncogene
13%
Association
12%
Cohort Study
12%
Gene Expression
11%
Transcriptomics
10%
DNA Methylation
10%
Sequencing
10%
Transcriptome
9%
Clinical Trial
8%
Synthesis
8%
Taxonomy
7%
Small Interfering RNA
7%
Learning
7%
Evolution
7%
Homologous Recombination
7%
Methylation
7%
Functional Genomics
7%
GLUT1
7%
Staining
6%
Cancer Cell
6%
Drug Resistance
6%
Staging
6%
Genome Sequencing
5%
Apoptosis
5%
Microsatellite Instability
5%
Vitamin D
5%
HDAC6
5%
High Throughput Screening
5%
Dynamics
5%
Base Excision Repair
5%
Inhibitor of Apoptosis
5%
Caspase 3
5%
Smoking
5%
Glucose Transporter
5%
Coding
5%
Receptor Tyrosine Kinase
5%
Somatic Mutation
5%
Receptor Tyrosine Kinase Inhibitors
5%
Prospective Cohort Study
5%
Autophagy
5%
Immune Checkpoints
5%
Ubiquitin Ligase
5%
Pharmacology, Toxicology and Pharmaceutical Science
Esophageal Adenocarcinoma
38%
Chemotherapy
35%
Malignant Neoplasm
25%
Biological Marker
23%
Survival
22%
Adenocarcinoma
16%
Colorectal Cancer
15%
Drug Resistance
12%
Drug Screening
10%
Pancreas Adenocarcinoma
10%
Capecitabine
10%
Cisplatin
7%
Oxaliplatin
7%
Neoplasm
7%
Diseases
7%
Protein P53
6%
Adverse Event
6%
Mitogen Activated Protein Kinase
6%
Overall Survival
6%
Firtecan
5%
Toxicity
5%
Galanin
5%
Fibroblast Growth Factor Receptor 4
5%
Gastrointestinal Toxicity
5%
Capecitabine Plus Oxaliplatin
5%
Bortezomib
5%
Galanin Receptor 1
5%
Prostaglandin Endoperoxide
5%
Histone Deacetylase 6
5%
Sapitinib
5%
Receptor
5%
DNA
5%
Stomach Cancer
5%
DNA A
5%
Protein Tyrosine Kinase
5%
Barrett Esophagus
5%
Epidemiology
5%
Cohort Study
5%
Ethanol
5%
Esophagus Cancer
5%
Gastrointestinal Symptom
5%
Molecular Pathology
5%
Epirubicin
5%
Phase I Trials
5%
Carboplatin
5%
Adenocarcinoma
5%
Inhibitor of Apoptosis Protein
5%
Esophageal Adenocarcinoma
5%
Lymph Node Metastasis
5%